MedTrace Logo

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

NCT05715814 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-05-01

No results posted yet for this study

Summary

The primary aim of this study is to determine the safety and mechanisms of SGLT2 inhibition in individuals on peritoneal dialysis (PD) with residual kidney function (RKF).

Conditions

  • Peritoneal Dialysis Complication
  • End Stage Kidney Disease
  • Sodium-glucose Co-transporter-2 Inhibitors
  • Kidney Dysfunction
  • Residual Kidney Function

Interventions

DRUG

Empagliflozin 25 MG

PO once daily

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Sunita KS Singh, MD MSc FRCPC · University Health Network, Toronto General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2027-05-01
Completion
2027-12-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05715814 on ClinicalTrials.gov